Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial

Published:2023-12 Issue: Volume:66 Page:102303
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Matsuzawa Reiko,Morise Masahiro^ORCID,Ito Kentaro^ORCID,Hataji Osamu,Takahashi Kosuke,Koyama Junji,Kuwatsuka Yachiyo,Goto Yasuhiro^ORCID,Imaizumi Kazuyoshi,Itani Hidetoshi,Yamaguchi Teppei,Zenke Yoshitaka,Oki Masahide^ORCID,Ishii Makoto^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020

3. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

5. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations;American Society of Clinical Oncology Educational Book;2024-06

2. Influence of Previous Therapy for Neutropenia Caused by Combination Therapy of Ramucirumab and Docetaxel;Cancers;2024-05-30